國產新冠藥最低價每支2417元
格隆匯7月14日丨據21財經,首個國產新冠特效藥價格來了,首方也已落地。甘肅省公共資源交易中心發佈通知,對“新冠疫情防控救治藥品”安巴韋單抗注射液及羅米司韋單抗注射液進行應急掛網,自2022年7月12日導入甘肅省國家醫療保障信息平臺藥品和醫用耗材招採管理子系統供全省公立醫療機構採購,公示期爲2022年7月12日至7月14日。甘肅省信息顯示,這兩支單抗的掛網單價爲每支“不高於全國最低價2417元”,該藥物是騰盛博藥旗下子公司騰盛華創醫藥技術(北京)有限公司研發的新冠治療用藥,並於7月8日正式在國內上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.